All News

Clinical pharmacy pioneer Mary Anne Koda-Kimble, PharmD, and Congressman Henry Waxman (D-Calif.) were among those honored last weekend at the Annual Meeting and Exposition of the American Pharmacists Association (APhA) in Washington, D.C.

Letters: March 2010

Pharmacists speak out about the pharmacist shortage and professional organizations.

FDA recommended drastic changes limiting the way long-acting beta2-adrenergic agonists are used to treat asthma.

After four decades of practice, the author offers some observations about the search for professional satisfaction and meaning in pharmacy.

While the government deems that marijuana has a "high potential for abuse" and "has no currently accepted medical use," some states have undertaken initiatives to pass legislation permitting its use for pain control and for control of nausea and vomiting by cancer patients.

Technology now exists that can verify the contents of a drug vial or syringe, benefiting retailers, hospitals, and manufacturers.

Medication therapy management programs are intended to improve patient outcomes and reduce healthcare costs. Community pharmacist Tony Bastian offers a detailed report on how MTM is working at his pharmacy.

Pharmacy and Therapeutics committees around the country are taking a second look at what they're using for pediatric rehydration and how much they're willing to pay.

Cabazitaxel, an investigational compound under development by Sanofi-aventis, plus prednisone/prednisolone, is associated with overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease advanced after treatment with docetaxel-based chemotherapy.

Letters: February 2010

Pharmacists speak out about Medicaid patients, professional organizations, medication therapy management, and more.

Spotlight on oral care

Since February is National Children's Dental Health Month, it's an appropriate time to introduce new oral care products for children and adults.

Walgreens pushes back

Cutbacks to Washington's Medicaid reimbursements have resulted in Walgreens receiving below its cost or break-even point on nearly 95 percent of brand-name medications.